Follicular Lymphoma

There was a statistically significant change in the serum PCT concentration (p < 0.0001), which significantly increased on days 1 to 4 compared to the initial measurement 0. The increases in inflammatory markers shortly after obinotuzumab (anti-CD20 antibody) administration can be significantly high but are most often not related to the onset of infection and do not lead to any ill consequences in the treatment of lymphoproliferative disease.

these findings underscore the promise of FoxP3+ cell quantities as added value in prognosis and highlight the potential benefits of Treg-stimulating therapies in PTCLs.

We analyzed 125 patients with the following characteristics: median age, 61 years (55; 67), advanced-stage disease, 88.8%; high FLIPI, 49.6%; TMTV, > 510 cm3; B2M, > 3 mg/L (24.8%); and R-CHOP-like treatment, 86.4%...Patients at intermediate and high risk according to the TMTV/B2M score were at high risk of disease progression within 24 months of treatment initiation (HR = 2.45 &lsqb;95% CI: 1.23-4.85] and HR = 3.75 &lsqb;95% CI: 1.7-8.2], respectively). This TMTV/B2M score may identify patients with the highest unmet medical needs.

P2, N=76, Active, not recruiting, Seoul National University Hospital | Recruiting --> Active, not recruiting

P=N/A, N=750, Not yet recruiting, University of Nottingham

P1/2, N=237, Recruiting, Hoffmann-La Roche | Trial completion date: Nov 2027 --> Oct 2030 | Trial primary completion date: Nov 2025 --> Oct 2028

P1/2, N=38, Completed, Prof. Dr. Clemens Schmitt | Active, not recruiting --> Completed | Trial primary completion date: Jun 2024 --> Nov 2024

P1/2, N=60, Recruiting, Enterome | Trial completion date: Sep 2029 --> May 2032 | Trial primary completion date: Jun 2025 --> May 2026

The complete response rate was 25.0% and 42.9% in the lenalidomide 15- and 20-mg cohorts, respectively. Due to acceptable toxicity and preliminary efficacy, the lenalidomide 20-mg dose was selected for further investigation.

P1/2, N=543, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

P1, N=54, Recruiting, Roswell Park Cancer Institute | N=36 --> 54

P=N/A, N=200, Recruiting, Rennes University Hospital | Not yet recruiting --> Recruiting

P=N/A, N=6, Active, not recruiting, University College, London | Trial completion date: May 2024 --> Jun 2025

P1/2, N=89, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Oct 2026 --> Feb 2026

P3, N=294, Not yet recruiting, Eastern Cooperative Oncology Group

P1/2, N=81, Recruiting, University of Sao Paulo | Not yet recruiting --> Recruiting

P1/2, N=11, Completed, Mayo Clinic | Active, not recruiting --> Completed

P3, N=128, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Dec 2027 --> Aug 2027

These include single-agent brentuximab vedotin, histone deacetylase inhibitors, duvelisib, ruxolitinib, EZH2 inhibitors, and azacitidine, among others. Follicular helper T-cell lymphomas, given frequent mutations in epigenetic regulator genes, may preferentially respond to agents such as histone deacetylase inhibitors, EZH2 inhibitors, and hypomethylating agents. As these therapies evolve in their use for both relapsed/refractory disease and then into frontline treatment, subtype-specific therapy will likely help personalize care for patients with PTCL.

Therefore, EZH2 inhibition enhances CAR-T cell efficacy through direct effects on CAR-T cells, in addition to rendering lymphoma B cells immunogenic. This approach is currently being evaluated in two clinical trials, NCT05934838 and NCT05994235, to improve immunotherapy outcomes in B cell lymphoma patients.

Treatment included R-CHOP (n=26), R-DA EPOCH (n=2), MTR (n=1), and R-MPV (n=1).26.66% had PD-L1 <1% while 73.33% had PD-L1 ≥1%; 33.33% had PD-L1 <5%, while 66.67% had PD-L1 ≥5%...Limitations include small number of patients, short follow up and inclusion of 2 patients of primary CNS lymphoma, that might have affected the analysis minimally. Further research is essential to standardize the cutoff value and scoring method.

Base substitution or indel variants were detected in TP53 (28% of cases), KMT2D (25%), CREBBP (14%), EZH2 (8%), MYD88 (8%), TNFRSF14 (8%), ATM (8%), NOTCH1 (7%), ARID1A (6%), B2M (6%), TNFAIP3 (6%), PIM1 (4%), CD79B (3%), BTK (2%, 97% of which were C481X ibrutinib resistance mutations in cases of CLL), MEF2B (2%), BCL2 (1%), and PLCG2 (1%)...Overall, 75% of FLs harbored a canonical IGH : : BCL2 rearrangement and 86% of MCLs harbored a canonical IGH : : CCND1 rearrangement.Conclusions : This analysis of 3,692 samples demonstrated that the F1H assay platform reliably detects a broad landscape of genomic alterations across a range of mature B-cell lymphoma/leukemia subtypes. By detecting all classes of genomic alterations in a single sequencing reaction, F1H provides an important advantage over single-gene and small-panel molecular tests in an era when the diagnosis, prognosis, and treatment of hematological malignancies increasingly rely on assessing the presence, as well as the absence, of numerous genomic alterations.

Adjuvant R-CVP and elevated intratumoural CD8 expression were independently associated with sustained disease control after radiotherapy in ESFL.

P3, N=700, Recruiting, Janssen Research & Development, LLC | Enrolling by invitation --> Recruiting

P1/2, N=230, Active, not recruiting, Taiho Oncology, Inc. | Trial completion date: Oct 2024 --> Dec 2025

P3, N=500, Recruiting, Genmab | Trial completion date: Jun 2030 --> Oct 2030 | Trial primary completion date: Nov 2029 --> Oct 2030

P3, N=900, Recruiting, Genmab | Trial primary completion date: Sep 2028 --> Jun 2027

Gallbladder follicular lymphoma is difficult to diagnose preoperatively, however, extra-regional lymph node swelling and relatively low apparent diffusion coefficients on magnetic resonance imaging can help its diagnosis.

P2, N=184, Recruiting, Genmab | Trial completion date: May 2029 --> Mar 2027 | Trial primary completion date: May 2029 --> Mar 2027

P3, N=1080, Recruiting, Genmab | Trial completion date: May 2037 --> Nov 2037 | Trial primary completion date: May 2037 --> Nov 2037

P2, N=622, Recruiting, Genmab | Trial completion date: Nov 2032 --> Jun 2031 | Trial primary completion date: Nov 2032 --> Jun 2031

Differential expression of most proteins was also associated with shorter transformation-free survival (p < 0.05). These findings emphasize underlying differences in FL biology predictive of subsequent transformation, highlighting deregulation of important interconnected cellular pathways.

P1, N=46, Not yet recruiting, Mayo Clinic

P1, N=18, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2026 --> Feb 2025 | Trial primary completion date: Oct 2026 --> Feb 2025

No abstract available

P2, N=240, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P1, N=231, Recruiting, AstraZeneca | N=116 --> 231

P1, N=100, Recruiting, Byondis B.V. | Trial primary completion date: Oct 2024 --> Oct 2025

P2, N=20, Recruiting, Tianjin Medical University Cancer Institute and Hospital

P1, N=18, Not yet recruiting, GenomeFrontier Therapeutics TW Co., Ltd.

P1/2, N=20, Active, not recruiting, University of Texas Southwestern Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Dec 2024 --> Aug 2024

This review aims to provide a comprehensive overview of AITL, including its clinical presentation, epidemiology, pathogenesis, histomorphology and treatment options. Despite advancements in the understanding of AITL biology and the development of novel treatment strategies, the prognosis for patients with AITL remains poor.